Caifeng F. Li
Expertise in
5
conditions

Caifeng F. Li

No. 56, Nan Li Shi Road, 
Beijing, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
No. 56, Nan Li Shi Road, 
Beijing, CN 

Overview

Caifeng Li practices practicing medicine in Beijing, China.

Li is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis, Blau Syndrome, Systemic Lupus Erythematosus (SLE), and Bone Marrow Aspiration.

They are actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 56, Nan Li Shi Road, Beijing, 100045, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

51 Total Publications

Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study.
Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study.
Journal: Rheumatology and therapy
Published: December 17, 2025

Frequently Asked Questions about Caifeng F. Li

Is Caifeng F. Li a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Caifeng F. Li is classified as an Advanced expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Caifeng F. Li participate in research or clinical trials?

Yes. Caifeng F. Li has published 51 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Caifeng F. Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
      View All 36 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile